指南与共识胸部肿瘤放疗中枢神经肿瘤放疗姑息放疗与转移瘤

ESTRO-EORTC 专家指南:I-III 期小细胞肺癌靶区勾画与放疗细节

ESTRO-EORTC expert guideline on target delineation and radiotherapy details for stage I-III small cell lung cancer.
指南 / 共识 · Radiother Oncol · 2026-04-01

该指南由 ESTRO 指南委员会与 EORTC 肺癌组组织欧洲专家制定,针对 I-III 期局限期小细胞肺癌的放疗实践提出推荐。内容涵盖分期(PET-CT 与脑 MRI)、胸部放疗时机与剂量方案、IMRT/VMAT 等技术、同步铂类-依托泊苷化疗后度伐利尤单抗巩固、预防性脑照射及 SBRT 等特定情形,旨在标准化放疗并 harmonize 临床试验设计。

要点

  • 准确分期应包括 PET-CT 和脑 MRI。
  • 胸部放疗宜在化疗早期开始,标准方案为 45 Gy/30 次(BID)或 66 Gy/33 次(每日一次)。
  • 适合患者采用同步铂类-依托泊苷 4-6 周期后度伐利尤单抗巩固至多 2 年,PCI 仍是治疗反应后的标准。

核心结论

  • 该更新版欧洲指南为 I-III 期小细胞肺癌提供标准化高质量放疗框架,并作为统一放疗实践和未来临床试验设计的参考标准。

研究设计与样本

  • 由 ESTRO 指南委员会与 EORTC 肺癌组组织欧洲专家组,回顾现有证据并制定推荐。

主要发现

  • 准确分期应包括 PET-CT 和脑 MRI。
  • 胸部放疗应在化疗期间早期开始。
  • 标准剂量方案包括 45 Gy 分 30 次(BID)或 66 Gy 分 33 次每日一次。
  • 采用 IMRT/VMAT 等适形技术、累及野淋巴结照射、呼吸运动管理(如 4D-CT、屏气)和图像引导(如 CBCT)。
  • 适合患者同步铂类-依托泊苷 4-6 周期后度伐利尤单抗巩固至多 2 年;治疗反应后 PCI 仍是标准方法。

关键数值与推荐

  • 准确分期应包括 PET-CT 和脑 MRI。
  • 胸部放疗标准剂量为 45 Gy/30 次(BID)或 66 Gy/33 次每日一次。
  • 同步化疗为铂类-依托泊苷 4-6 周期,随后度伐利尤单抗巩固至多 2 年。
  • 治疗反应后 PCI 继续作为标准方法;海马保护 PCI 和 MRI 监测策略正在研究中。
  • 特定情况下,医学不可手术早期无淋巴结受累者可考虑 SBRT;R1 切除或 pN2 受累可考虑辅助放疗。

临床怎么用

  • 分期应包含 PET-CT 与脑 MRI 以准确分期。
  • 胸部放疗宜在化疗早期启动,选用 45 Gy/30 次 BID 或 66 Gy/33 次每日一次方案。
  • 采用 IMRT/VMAT、累及野照射、呼吸运动管理和图像引导等技术实施放疗。
  • 适合患者行同步铂类-依托泊苷化疗后度伐利尤单抗巩固,治疗反应后考虑 PCI。
  • 特定早期无淋巴结受累不可手术者可考虑 SBRT,R1 切除或 pN2 受累可考虑辅助放疗。

局限性

  • 海马保护 PCI 和 MRI 监测策略仍在进行中的研究中评估。
  • 适应性放疗、剂量递增和精准医学整合等新兴策略有待进一步研究。
  • 与免疫治疗和/或新型药物(如 DLL3 靶向治疗)的整合正在积极研究中。
  • 生物标志物指导的治疗个体化仍处于研究阶段。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Stage I-III limited-stage small cell lung cancer (SCLC) is a highly aggressive yet potentially curable disease with concurrent chemoradiotherapy. Thoracic radiation therapy (RT) plays a central role in the management of stage I-III SCLC; however significant variation exists in staging, target volume delineation, dose prescription, and integration with systemic therapy. This document provides an updated European recommendations on the use of RT in stage I-III SCLC, reflecting recent evidence and advancements in clinical practice. MATERIAL AND METHODS: A panel of European experts was convened under the auspices of the ESTRO Guidelines Committee, in collaboration with EORTC Lung Cancer Group, and to review the available evidence and develop recommendations. Key topics addressed included disease staging, radiotherapy planning and delivery, and the integration with chemotherapy and immunotherapy. RESULTS: Accurate staging should include PET-CT and brain MRI. Thoracic RT should be initiated early during chemotherapy. Standard dose schedules include 45 Gy in 30 fractions (BID) or 66 Gy in 33 fractions once daily, using conformal techniques such as IMRT/VMAT, involved field nodal irradiation, respiratory motion management (e.g., 4D-CT, breath-hold) and image guidance (e.g., cone-beam CT [CBCT]). Concurrent chemotherapy with 4-6 cycles platinum-etoposide followed by consolidation durvalumab for up to two years is the standard of care in fit patients. Prophylactic cerebral irradiation (PCI) continues to represent the standard approach following treatment response; while hippocampal-sparing PCI and MRI surveillance strategies are being actively evaluated in ongoing studies. In selected cases, stereotactic body radiotherapy (SBRT) may be appropriate for medically inoperable early-stage disease without nodal involvement, and adjuvant RT can be considered for R1 resections or pN2 involvement. Emerging strategies, including adaptive RT, dose escalation and the integration of precision medicine have the potential to improve the therapeutic ratio. Integration with immunotherapy and/or novel agents, such as delta-like ligand 3 (DLL3)-targeted therapies, is under active investigation. Biomarker-guided treatment personalisation remains investigational. CONCLUSIONS: These updated European guidelines provide a comprehensive framework for standardized, high-quality care in stage I-III SCLC and establish a reference standard to harmonize radiotherapy approaches and inform the design of upcoming clinical trials.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Levy A, Le Péchoux C, Grønberg B, et al. ESTRO-EORTC expert guideline on target delineation and radiotherapy details for stage I-III small cell lung cancer. Radiother Oncol. 2026. PMID: 41932500. doi:10.1016/j.radonc.2026.111516

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。